Neuroinflammation, immune system and Alzheimer disease: searching for the missing link

Aging Clinical and Experimental Research

Volumn 29, Issue 5, 2017, Pages 821-831

  Guerriero, F ^a,b   Sgarlata, C ^a   Francis, M ^a   Maurizi, N ^a   Faragli, A ^a   Perna, S ^a   Rondanelli, M ^a   Rollone, M ^b   Ricevuti, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b ASP (Azienda di Servizi alla Persona) of Pavia   (Italy)

Author keywords

Alzheimer disease; Blood brain barrier; Derived microglia microvesicles; Inflammasome; Neuroinflammation; Signalosome

Indexed keywords

ESTROGEN; INFLAMMASOME; PROTEIN; SIGNALOSOME; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MEMBRANE MICROPARTICLE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PERMEABILITY BARRIER; REVIEW; T LYMPHOCYTE; ASTROCYTE; DISEASE EXACERBATION; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASTROCYTES; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; MICROGLIA;

EID: 84990937734     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-016-0637-z     Document Type: Review

References (81)

1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
2. Fratiglioni L, Winblad B, von Strauss E (2007) Prevention of Alzheimer’s disease and dementia. Major findings from the Kungsholmen Project. Physiol Behav 92:98–104
3. Kinsella K, Velkoff VA (2002) The demographics of aging. Aging Clin Exp Res 14:159–169
4. Rogers J, Cooper NR, Webster S et al (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89:10016–10020
5. McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126:479–497
6. Heneka MT, O’banion MK (2007) Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 184:69–91
7. Damani MR, Zhao L, Fontainhas AM et al (2011) Age-related alterations in the dynamic behavior of microglia. Aging Cell 10:263–276
8. Sierra A, Gottfried-Blackmore AC, Mc Ewen BS et al (2007) Microglia derived from aging mice exhibit altered inflammatory profile. Glia 55:412–424
9. Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139:313–326
10. Parihar MS, Brewer GJ (2007) Simultaneous age-related depolarization of mitochondrial membrane potential and increased mitochondrial reactive oxygen species production correlate with age-related glutamate excitotoxicity in rat hippocampal neurons. J Neurosci Res 85:1018–1032
11. Kierdorf K, Prinz M (2013) Factors regulating microglia activation. Front Cell Neurosci 7:44
12. Czlonkowska A, Kurkowska-Jastrzebska I (2011) Inflammation and gliosis in neurological diseases–clinical implications. J Neuroimmunol 231:78–85
13. Liu W, Tang Y, Feng J (2011) Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system. Life Sci 89:141–146
14. Cras P, Smith MA, Richey PL et al (1995) Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 89:291–295
15. Seubert P, Vigo-Pelfrey C, Esch F et al (1992) Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature 359:325–327
16. Sardi F, Fassina L, Venturini L et al (2011) Alzheimer’s disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 11:149–153
17. Tejera D, Heneka MT (2016) Microglia in Alzheimer’s disease: the good, the bad and the ugly. Curr Alzheimer Res 13:370–380
18. Abbott NJ, Patabendige AA, Dolman DE et al (2010) Structure and function of the blood brain barrier. Neurobiol Dis 37:13–25
19. Crane IJ, Liversidge J (2008) Mechanism of leukocyte migration across the blood–retina-barrier. Semin Immunopathol 30:165–177
20. Sallusto F, Impellizieri D, Basso C et al (2012) T-cell trafficking in the central nervous system. Immunol Rev 248:216–227
21. Engelhardt B, Coisne C (2011) Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8:4
22. Lyck R, Engelhardt B (2012) Going against the tide—how encephalitogenic T cells breach the blood brain barrier. J Vasc Res 49:497–509
23. Von Andrian UH, Mackay CR (2000) T-cell function and migration. Two sides of the same coin. N Engl J Med 343:1020–1034
24. Hickey WF, Hsu BL, Kimura H (1991) T lymphocyte entry into the central nervous system. J Neurosci Res 28:254–260
25. Owens T, Bechmann I, Engelhardt B (2008) Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol 67:1113–1121
26. Steiner O (2010) Differential roles for endothelial ICAM-1, ICAM-2 and VCAM-1 in shear resistant T cell arrest, polarization, and directed crawling on BBB endothelium. J Immunol 185:4846–4855
27. Bauer M, Brakebusch C, Coisne C et al (2009) Beta 1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci USA 106:1920–1925
28. Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 11:288–300
29. Bullard DC, Hu X, Schoeb TR et al (2007) Intercellular adhesion molecule-1 expression is required on multiple cell types for development of experimental autoimmune encephalomyelitis. J Immunol 178:851–857
30. Cashman JR, Ghirmai S, Abel KJ et al (2008) Immune defects in Alzheimer’s disease: new medications development. BMC Neurosci 9(Suppl 2):S13
31. Saresella M, Calabrese E, Marventano I et al (2010) PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer’s disease. J Alzheimer Dis 21:927–938
32. Wang L, Xie Y, Zhu LJ et al (2010) An Association between immunosenescence and CD4+ CD25+ regulatory T Cells: a systematic review. Biomed Environ Sci 23:327–332
33. Larbia A, Paweleca G, Witkowskib JM et al (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J Alzheimer Dis 17:91–103
34. Hanke ML, Kielian T (2011) Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci 121:367–387
35. Landreth GE, Reed-Geaghan EG (2009) TLRs in Alzheimer’s disease. Curr Top Microbiol Immunol 336:137–153
36. Riazi K, Galic MA, Pittman QJ (2010) Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 89:34–42
37. Asari Y, Majima M, Sugimoto K et al (1996) Release site of TNF alpha after intravenous and intraperitoneal injection of LPS from Escherichia coli in rats. Shock 5:208–212
38. Ho Y, Lin Y, Wu C et al (2015) Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus. J Biomed Sci 22:46
39. Goehler LE, Gaykema RP, Nguyen KT et al (1999) Interleukin-1beta in immune cells of the abdominal vagus nerve: A link between the immune and nervous systems? J Neurosci 19:2799–2806
40. Nakano Y, Furube E, Morita S et al (2015) Astrocytic TLR4 expression and LPS-induced nuclear translocation of STAT3 in the sensory circumventricular organs of adult mouse brain. J Neuroimmunol 278:144–158
41. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69
42. Nguyen MD, D’Aigle T, Gowing G et al (2004) Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 24:1340–1349
43. Chen Z, Jalabi W, Shpargel KB et al (2012) Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 32:11706–11715
44. Henry CJ, Huang Y, Wynne AM et al (2009) Peripheral lipopolysaccharide challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 23:309–317
45. Liu X, Wu Z, Hayashi Y et al (2012) Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. Neuroscience 216:133–142
46. Turola E, Furlan R, Bianco F et al (2012) Microglial Microvesicle Secretion and Intercellular Signaling. Front Physiol 3:149
47. Rajendran L, Honsho M, Zahn TR et al (2006) Proc Natl Acad Sci USA 2006:11172–11177
48. Bianco F, Pravettoni E, Colombo A et al (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268–7277
49. 7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts. FASEB J 23:795–805
50. Antonucci F, Turola E, Riganti L et al (2012) Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J 31:1240
51. Verderio C, Muzio L, Turola E et al (2012) Myeloid microvesicles are a marker and a therapeutic target for neuroinflammation. Ann Neurol 72:610–624
52. Joshi P, Turola E, Ruiz A et al (2014) Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ 21:582–593
53. Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161
54. Kayagaki N, Warming S, Lamkanfi M et al (2011) Non-canonical inflammasome activation targets caspase-11. Nature 479:117–121
55. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2:417–426
56. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229–265
57. Petrilli V, Papin S, Dostert C et al (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14:1583–1589
58. Thomas PG, Dash P, Aldridge JR et al (2009) NLRP3 (NALP3/CIAS1/Cryopyrin) mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30:566–575
59. Halle A, Hornung V, Petzold GC et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol 9:857–865
60. Masters SL (2012) Specific inflammasomes in complex diseases. Clin Immunol 147:223–228
61. Heneka MT, Kummer MP, Stutz A et al (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493:674–678
62. Marin R (2011) Signalosomes in the brain: relevance in the development of certain neuropathologies such as Alzheimer’s disease. Front Physiol 2:23
63. Marin R, Guerra B, Alonso R et al (2005) Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res 2:287–301
64. Guerra B, Diaz M, Alonso R et al (2004) Plasma membrane estrogen receptor mediates neuroprotection against β-amyloid toxicity through activation of Raf1/MEK/ERK cascade in septal-derived cholinergic SN56 cells. J Neurochem 91:99–1099
65. Ramirez CM, Gonzalez M, Diaz M et al (2009) VDAC and ERα interaction in caveolae from human cortex is altered in Alzheimer’s disease. Mol Cell Neurosci 42:172–183
66. Amtul Z, Wang L, Westaway D et al (2010) Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer’s disease. Neuroscience 169:781–786
67. Yue X, Lu M, Lancaster T et al (2005) Brain estrogen deficiency accelerates A(beta) plaque formation in an Alzheimer’s disease animal model. Proc Natl Acad Sci USA 102:19198–19203
68. Alvarez-De-La-Rosa M, Silva I, Nilsen J et al (2005) Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer’s disease. Ann NY Acad Sci 1052:210–224
69. Pike CJ, Carroll JC, Rosario ER et al (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30:239–258
70. Simpkins JW, Yi KD, Yang SH et al (2010) Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta 1800:1113–1120
71. Pike CJ (1999) Estrogen modulates neuronal Bcl-xL expression and β-amyloid-induced apoptosis: relevance to Alzheimer’s disease. J Neurochem 72:1552–1563
72. Nilsen J (2008) Estradiol and neurodegenerative oxidative stress. Front Neuroendocrinol 29:463–475
73. Borras C, Sastre J, Garcia-Sala D et al (2003) Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic Biol Med 34:546–552
74. Barha CK, Galea LA (2010) Influence of different estrogens on neuroplasticity and cognition in the hippocampus. Biochim Biophys Acta 1800:1056–1067
75. Foy MR, Baudry M, Diaz Brinton R et al (2008) Estrogen and hippocampal plasticity in rodent models. J Alzheimers Dis 15:589–603
76. Goodman Y, Bruce AJ, Cheng B et al (1996) Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 66:1836–1844
77. Morrison JH, Baxter MG (2012) The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci 13:240–250
78. Nilsen J, Irwin RW, Gallaher TK et al (2007) Estradiol in vivo regulation of brain mitochondrial proteome. J Neurosci 27:14069–14077
79. Asthana S, Baker LD, Craft S et al (2001) High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 57:605–612
80. Schneider LS, Farlow MR, Henderson VW et al (1996) Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 46:1580–1584
81. D’Andrea MR (2005) Add Alzheimer’s disease to the list of autoimmune diseases. Med Hypotheses 64:458–463